Exploring the neuroprotection of the combination of astragaloside A, chlorogenic acid and scutellarin in treating chronic cerebral ischemia via network analysis and experimental validation

Exploring the neuroprotection of the combination of astragaloside A, chlorogenic acid and scutellarin in treating chronic cerebral ischemia via network analysis and experimental validation

Chronic cerebral ischemia (CCI) primarily causes cognitive dysfunction and other neurological impairments, yet there remains a lack of ideal therapeutic medications. The preparation combination of Astragalus membranaceus (Fisch.) Bunge and Erigeron breviscapus (Vant.) Hand.-Mazz have been utilized t...

Full description

Bibliographic Details
Main Authors:	Fang Cheng, Jie Zhang, Pan Yang, Zufei Chen, Yinghao Fu, Jiajia Mi, Xingliang Xie, Sha Liu, Yanmei Sheng
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Heliyon
Subjects:	Chronic cerebral ischemia Astragaloside A Chlorogenic acid and scutellarin combination Network analysis PI3K/AKT pathway Apoptosis
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844024051934

Similar Items

An Efficient Chemical Synthesis of Scutellarein: An in Vivo Metabolite of Scutellarin
by: Ze-Xi Dong, et al.
Published: (2016-02-01)

The Role of Astragaloside IV against Cerebral Ischemia/Reperfusion Injury: Suppression of Apoptosis via Promotion of P62-LC3-Autophagy
by: Yi Zhang, et al.
Published: (2019-05-01)

Preparation and characterization of scutellarin loaded on ultradeformable nano-liposomes scutellarin EDTMP (S-UNL-E) and in vitro study of its osteogenesis
by: Teng Minhua, et al.
Published: (2022-01-01)

Research Progress on the Ability of Astragaloside IV to Protect the Brain Against Ischemia-Reperfusion Injury
by: Xianhui Kang, et al.
Published: (2021-11-01)

Effect of Scutellarin on Melanoma B16 in Vitro and in Vivo and Its Mechanism
by: Chongchong TIAN, et al.
Published: (2023-09-01)

Astragaloside IV promotes cerebral angiogenesis and neurological recovery after focal ischemic stroke in mice via activating PI3K/Akt/mTOR signaling pathway
by: Guang Shi, et al.
Published: (2023-12-01)

Synthesis and Protective Effect of Scutellarein on Focal Cerebral Ischemia/Reperfusion in Rats
by: Nian-Guang Li, et al.
Published: (2012-09-01)

Current advances on the therapeutic potential of scutellarin: an updated review
by: Yifei Xie, et al.
Published: (2024-03-01)

Cyclodextrin pendant polymer as an efficient drug carrier for scutellarin
by: Rongqiang Liao, et al.
Published: (2020-01-01)

Effect of Scutellarin on Promoting the Sensitivity of Breast Cancer 4T1 Cells to Cisplatin in Vitro and in Vivo
by: Qi ZHANG, et al.
Published: (2024-03-01)

Oral Scutellarin Treatment Ameliorates Retinal Thinning and Visual Deficits in Experimental Glaucoma
by: Jingyuan Zhu, et al.
Published: (2021-08-01)

Neuroprotective effects of metformin on cerebral ischemia‐reperfusion injury by regulating PI3K/Akt pathway
by: Cailian Ruan, et al.
Published: (2021-10-01)

Endothelial Progenitor-Cell-Derived Exosomes Induced by Astragaloside IV Accelerate Type I Diabetic-wound Healing via the PI3K/AKT/mTOR Pathway in Rats
by: Wu Xiong, et al.
Published: (2023-11-01)

Pharmacokinetic Comparison of Scutellarin and Paeoniflorin in Sham-Operated and Middle Cerebral Artery Occlusion Ischemia and Reperfusion Injury Rats after Intravenous Administration of Xin-Shao Formula
by: Yueting Li, et al.
Published: (2016-09-01)

A Mechanistic Exploratory Study on the Therapeutic Efficacy of Astragaloside IV Against Diabetic Retinopathy Revealed by Network Pharmacology
by: Zhi-Hao Zhao, et al.
Published: (2022-06-01)

Studies on tissue distribution of scutellarin and methyl polyethylene glycol (mPEG)-scutellarin prodrug in mice
by: Juan Lu, et al.
Published: (2012-06-01)

A UPLC-ESI-MS/MS Method for Simultaneous Quantitation of Chlorogenic Acid, Scutellarin, and Scutellarein in Rat Plasma: Application to a Comparative Pharmacokinetic Study in Sham-Operated and MCAO Rats after Oral Administration of Erigeron breviscapus Extract
by: Siying Chen, et al.
Published: (2018-07-01)

Ultrasonic extraction and purification of scutellarin from Erigerontis Herba using deep eutectic solvent
by: Yong-jing Liu, et al.
Published: (2023-10-01)

Astragaloside positively regulated osteogenic differentiation of pre-osteoblast MC3T3-E1 through PI3K/Akt signaling pathway
by: Wei Bing Jing, et al.
Published: (2021-10-01)

Effects of scutellarin on the mechanism of cardiovascular diseases: a review
by: Xinyu Zhang, et al.
Published: (2024-01-01)

Protective effect of scutellarin on myocardial infarction induced by isoprenaline in rats
by: Haibo Huang, et al.
Published: (2018-03-01)

Flavonoid scutellarin positively regulates root length through NUTCRACKER
by: Xing Huang, et al.
Published: (2021-06-01)

The Effect of Astragaloside on Pacemaker Current and the Cytoskeleton in Rabbit Sinoatrial Node Cells Under the Ischemia and Reperfusion Condition
by: Ruxiu Liu, et al.
Published: (2018-05-01)

Astragaloside IV Inhibits Adipose Lipolysis and Reduces Hepatic Glucose Production via Akt Dependent PDE3B Expression in HFD-Fed Mice
by: Qun Du, et al.
Published: (2018-01-01)

A New and Efficient Synthesis of 6-O-Methylscutellarein, the Major Metabolite of the Natural Medicine Scutellarin
by: Wei Zhang, et al.
Published: (2015-06-01)

Scutellarin ameliorates neonatal hypoxic-ischemic encephalopathy associated with GAP43-dependent signaling pathway
by: Rui-Ze Niu, et al.
Published: (2021-10-01)

The combination of Tanshinone IIA and Astragaloside IV attenuates myocardial ischemia–reperfusion injury by inhibiting the STING pathway
by: Pan Zhai, et al.
Published: (2024-02-01)

A Preclinical Systematic Review and Meta-Analysis of Astragaloside IV for Myocardial Ischemia/Reperfusion Injury
by: Qun Zheng, et al.
Published: (2018-07-01)

Astragalosidic Acid: A New Water-Soluble Derivative of Astragaloside IV Prepared Using Remarkably Simple TEMPO-Mediated Oxidation
by: Lin-Sen Qing, et al.
Published: (2017-07-01)

Scutellarin Alleviates Ischemic Brain Injury in the Acute Phase by Affecting the Activity of Neurotransmitters in Neurons
by: Chunguo Wang, et al.
Published: (2023-04-01)

Scutellarin Reduce the Homocysteine Level and Alleviate Liver Injury in Type 2 Diabetes Model
by: Yiyu Wang, et al.
Published: (2020-12-01)

Neuroprotective Effect of Danhong Injection on Cerebral Ischemia-Reperfusion Injury in Rats by Activation of the PI3K-Akt Pathway
by: Chen Feng, et al.
Published: (2020-03-01)

Scutellarin Increases Cisplatin-Induced Apoptosis and Autophagy to Overcome Cisplatin Resistance in Non-small Cell Lung Cancer via ERK/p53 and c-met/AKT Signaling Pathways
by: Chao-Yue Sun, et al.
Published: (2018-02-01)

Cerebral ischemia reperfusion injury: from public health perspectives to mechanisms
by: Gulnara Kapanova, et al.
Published: (2022-11-01)

Astragaloside IV: A promising natural neuroprotective agent for neurological disorders
by: Min Yao, et al.
Published: (2023-03-01)

Network pharmacology and in vitro experimental verification to reveal the mechanism of Astragaloside IV against kidney ischemia-reperfusion injury
by: Yan Guo, et al.
Published: (2023-11-01)

Scutellarin antagonizing retinal pigment epithelial cell damage induced by high glucose and its molecular mechanism
by: Hai-Feng Liu, et al.
Published: (2020-02-01)

Scutellarin inhibits caspase-11 activation and pyroptosis in macrophages via regulating PKA signaling
by: Jiezhou Ye, et al.
Published: (2021-01-01)

Glycoside scutellarin enhanced CD-MOF anchoring for laryngeal delivery
by: Kena Zhao, et al.
Published: (2020-09-01)

Anti-Fibrosis Effect of Scutellarin via Inhibition of Endothelial–Mesenchymal Transition on Isoprenaline-Induced Myocardial Fibrosis in Rats
by: Hao Zhou, et al.
Published: (2014-09-01)